These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558 [TBL] [Abstract][Full Text] [Related]
9. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965 [TBL] [Abstract][Full Text] [Related]
10. Third-line treatment and von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284 [TBL] [Abstract][Full Text] [Related]
11. [ Hofman MS; Emmett L; Sandhu S; Iravani A; Joshua AM; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Ng S; Francis RJ; Gedye C; Rutherford NK; Weickhardt A; Scott AM; Lee ST; Kwan EM; Azad AA; Ramdave S; Redfern AD; Macdonald W; Guminski A; Hsiao E; Chua W; Lin P; Zhang AY; McJannett MM; Stockler MR; Violet JA; Williams SG; Martin AJ; Davis ID; Lancet; 2021 Feb; 397(10276):797-804. PubMed ID: 33581798 [TBL] [Abstract][Full Text] [Related]
13. A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer. Leibowitz R; Davidson T; Gadot M; Aharon M; Malki A; Levartovsky M; Oedegaard C; Saad A; Sandler I; Ben-Haim S; Domachevsky L; Berger R Oncologist; 2020 Sep; 25(9):787-792. PubMed ID: 32430954 [TBL] [Abstract][Full Text] [Related]
14. [ Hofman MS; Violet J; Hicks RJ; Ferdinandus J; Thang SP; Akhurst T; Iravani A; Kong G; Ravi Kumar A; Murphy DG; Eu P; Jackson P; Scalzo M; Williams SG; Sandhu S Lancet Oncol; 2018 Jun; 19(6):825-833. PubMed ID: 29752180 [TBL] [Abstract][Full Text] [Related]
15. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624 [TBL] [Abstract][Full Text] [Related]
16. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis. Satapathy S; Mittal BR; Sood A Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129 [TBL] [Abstract][Full Text] [Related]
17. Radioligand Therapy With Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089 [No Abstract] [Full Text] [Related]
19. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis. Kim YJ; Kim YI Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428 [TBL] [Abstract][Full Text] [Related]
20. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]